Search

Your search keyword '"Saliby, Renee Maria"' showing total 132 results
Start Over Author "Saliby, Renee Maria"
132 results on '"Saliby, Renee Maria"'

1. Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma

Author

Jammihal, Tejas, Saliby, Renee Maria, Labaki, Chris, Soulati, Hanna, Gallegos, Juan, Peris, Arnau, McCurry, Dustin, Yu, Chunlei, Shah, Valisha, Poduval, Deepak, El Zarif, Talal, El Ahmar, Nourhan, Laimon, Yasmin Nabil, Eid, Marc, Sheshdeh, Aseman Bagheri, Krajewski, Katherine M., Büttner, Florian A., Schwab, Matthias, Heng, Daniel, Casellas, Rafael C., Rai, Kunal, Zacharias Millward, Niki M., Msaouel, Pavlos, Karam, Jose, Signoretti, Sabina, Van Allen, Eliezer, Choueiri, Toni K., Braun, David A., and Shukla, Sachet A.

Published
2025
Full Text
View/download PDF

2. Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.

Author

Johnson, Douglas B, Atkins, Michael B, Hennessy, Cassandra, Wise-Draper, Trisha, Heilman, Hannah, Awosika, Joy, Bakouny, Ziad, Labaki, Chris, Saliby, Renee Maria, Hwang, Clara, Singh, Sunny RK, Balanchivadze, Nino, Friese, Christopher R, Fecher, Leslie A, Yoon, James J, Hayes-Lattin, Brandon, Bilen, Mehmet A, Castellano, Cecilia A, Lyman, Gary H, Tachiki, Lisa, Shah, Sumit A, Glover, Michael J, Flora, Daniel B, Wulff-Burchfield, Elizabeth, Kasi, Anup, Abbasi, Saqib H, Farmakiotis, Dimitrios, Viera, Kendra, Klein, Elizabeth J, Weissman, Lisa B, Jani, Chinmay, Puc, Matthew, Fahey, Catherine C, Reuben, Daniel Y, Mishra, Sanjay, Beeghly-Fadiel, Alicia, French, Benjamin, Warner, Jeremy L, and COVID-19 and Cancer Consortium

Subjects
COVID-19 and Cancer Consortium, Humans, Melanoma, Multiple Organ Failure, Immunotherapy, COVID-19, Cancer, Immune therapy, Targeted therapy, Rehabilitation, Clinical Research, Lung, Rare Diseases, Good Health and Well Being, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

IntroductionCOVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy.MethodsUsing the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors.ResultsOf 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 - 1.39; targeted therapy OR 1.89, 95% CI 0.64 - 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 - 2.35).ConclusionsMelanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors.

Published
2023

3. Liquid biopsy epigenomic profiling for cancer subtyping

Author

Baca, Sylvan C., Seo, Ji-Heui, Davidsohn, Matthew P., Fortunato, Brad, Semaan, Karl, Sotudian, Shahabbedin, Lakshminarayanan, Gitanjali, Diossy, Miklos, Qiu, Xintao, El Zarif, Talal, Savignano, Hunter, Canniff, John, Madueke, Ikenna, Saliby, Renee Maria, Zhang, Ziwei, Li, Rong, Jiang, Yijia, Taing, Len, Awad, Mark, Chau, Cindy H., DeCaprio, James A., Figg, William D., Greten, Tim F., Hata, Aaron N., Hodi, F. Stephen, Hughes, Melissa E., Ligon, Keith L., Lin, Nancy, Ng, Kimmie, Oser, Matthew G., Meador, Catherine, Parsons, Heather A., Pomerantz, Mark M., Rajan, Arun, Ritz, Jerome, Thakuria, Manisha, Tolaney, Sara M., Wen, Patrick Y., Long, Henry, Berchuck, Jacob E., Szallasi, Zoltan, Choueiri, Toni K., and Freedman, Matthew L.

Published
2023
Full Text
View/download PDF

4. Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma

Author

El Zarif, Talal, Semaan, Karl, Eid, Marc, Seo, Ji-Heui, Garinet, Simon, Davidsohn, Matthew P., Sahgal, Pranshu, Fortunato, Brad, Canniff, John, Nassar, Amin H., Abou Alaiwi, Sarah, Bakouny, Ziad, Lakshminarayanan, Gitanjali, Savignano, Hunter, Lyons, Kevin, Matar, Sayed, Ali, Atef, Saad, Eddy, Saliby, Renee Maria, Cordeiro, Paulo, Zhang, Ziwei, El Ahmar, Nourhan, Laimon, Yasmin Nabil, Labaki, Chris, Shah, Valisha, Freeman, Dory, O’Toole, Jillian, Lee, Gwo-Shu Mary, Hwang, Justin, Pomerantz, Mark, Signoretti, Sabina, Van Allen, Eliezer M., Xie, Wanling, Berchuck, Jacob E., Viswanathan, Srinivas R., Braun, David A., Choueiri, Toni K., Freedman, Matthew L., and Baca, Sylvan C.

Published
2024
Full Text
View/download PDF

5. Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study

Author

Wagner, Michael J, Hennessy, Cassandra, Beeghly, Alicia, French, Benjamin, Shah, Dimpy P, Croessmann, Sarah, Vilar-Compte, Diana, Ruiz-Garcia, Erika, Ingham, Matthew, Schwartz, Gary K, Painter, Corrie A, Chugh, Rashmi, Fecher, Leslie, Park, Cathleen, Zamulko, Olga, Trent, Jonathan C, Subbiah, Vivek, Khaki, Ali Raza, Tachiki, Lisa, Nakasone, Elizabeth S, Loggers, Elizabeth T, Labaki, Chris, Saliby, Renee Maria, McKay, Rana R, Ajmera, Archana, Griffiths, Elizabeth A, Puzanov, Igor, Tap, William D, Hwang, Clara, Tejwani, Sheela, Jhawar, Sachin R, Hayes-Lattin, Brandon, Wulff-Burchfield, Elizabeth, Kasi, Anup, Reuben, Daniel Y, Nagaraj, Gayathri, Joshi, Monika, Polimera, Hyma, Kulkarni, Amit A, Esfahani, Khashayar, Kwon, Daniel H, Paoluzzi, Luca, Bilen, Mehmet A, Durbin, Eric B, Grivas, Petros, Warner, Jeremy L, and Davis, Elizabeth J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cancer, Prevention, Pediatric Cancer, Clinical Research, Pediatric, Pediatric Research Initiative, Aetiology, 2.4 Surveillance and distribution, Good Health and Well Being, sarcoma, COVID-19, SARS-CoV-2, CCC19, COVID-19 and Cancer Consortium, Oncology and carcinogenesis
Abstract

BackgroundPatients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19.MethodsWe performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed.Resultsof 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity.ConclusionsPatients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.

Published
2022

6. Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping

Author

Baca, Sylvan C., Seo, Ji-Heui, Davidsohn, Matthew P., Fortunato, Brad, Semaan, Karl, Sotudian, Shahabbedin, Lakshminarayanan, Gitanjali, Diossy, Miklos, Qiu, Xintao, El Zarif, Talal, Savignano, Hunter, Canniff, John, Madueke, Ikenna, Saliby, Renee Maria, Zhang, Ziwei, Li, Rong, Jiang, Yijia, Taing, Len, Awad, Mark, Chau, Cindy H., DeCaprio, James A., Figg, William D., Greten, Tim F., Hata, Aaron N., Hodi, F. Stephen, Hughes, Melissa E., Ligon, Keith L., Lin, Nancy, Ng, Kimmie, Oser, Matthew G., Meador, Catherine, Parsons, Heather A., Pomerantz, Mark M., Rajan, Arun, Ritz, Jerome, Thakuria, Manisha, Tolaney, Sara M., Wen, Patrick Y., Long, Henry, Berchuck, Jacob E., Szallasi, Zoltan, Choueiri, Toni K., and Freedman, Matthew L.

Published
2024
Full Text
View/download PDF

10. Germline variants associated with toxicity to immune checkpoint blockade

Author

Groha, Stefan, Alaiwi, Sarah Abou, Xu, Wenxin, Naranbhai, Vivek, Nassar, Amin H., Bakouny, Ziad, El Zarif, Talal, Saliby, Renee Maria, Wan, Guihong, Rajeh, Ahmad, Adib, Elio, Nuzzo, Pier V., Schmidt, Andrew L., Labaki, Chris, Ricciuti, Biagio, Alessi, Joao Victor, Braun, David A., Shukla, Sachet A., Keenan, Tanya E., Van Allen, Eliezer, Awad, Mark M., Manos, Michael, Rahma, Osama, Zubiri, Leyre, Villani, Alexandra-Chloe, Fairfax, Benjamin, Hammer, Christian, Khan, Zia, Reynolds, Kerry, Semenov, Yevgeniy, Schrag, Deborah, Kehl, Kenneth L., Freedman, Matthew L., Choueiri, Toni K., and Gusev, Alexander

Published
2022
Full Text
View/download PDF

11. Impact of β-adrenergic blockade on efficacy of immunotherapy in patients with metastatic clear cell renal cell carcinoma.

Author

Semaan, Karl, primary, Eid, Marc, additional, Saad, Eddy, additional, Issa, Wadih, additional, Saliby, Renee Maria, additional, Paul, Morgan, additional, Zhong, Caiwei, additional, Gunenc, Damla, additional, Phillips, Noa, additional, Nawfal, Rashad, additional, Machaalani, Marc, additional, El Hajj Chehade, Razane, additional, Yekeduz, Emre, additional, Labaki, Chris, additional, El Zarif, Talal, additional, Baca, Sylvan C., additional, Xie, Wanling, additional, McGregor, Bradley Alexander, additional, Zhang, Tian, additional, and CHOUEIRI, Toni K., additional

Published
2024
Full Text
View/download PDF

12. Investigation of T cell phenotypes associated with response or resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC).

Author

Kashima, Soki, primary, Ye, Zhaochen, additional, Meliki, Alia, additional, Hugaboom, Miya, additional, Schindler, Nicholas R., additional, Graham, Jess, additional, Moritz, Vivien, additional, El Ahmar, Nourhan, additional, Nabil Laimon, Yasmin, additional, Canniff, John, additional, Saliby, Renee Maria, additional, Lee, Gwo-Shu Mary, additional, Machaalani, Marc, additional, Sun, Maxine, additional, Xu, Wenxin, additional, Signoretti, Sabina, additional, McGregor, Bradley Alexander, additional, McKay, Rana R., additional, CHOUEIRI, Toni K., additional, and Braun, David A., additional

Published
2024
Full Text
View/download PDF

13. Association of a germline single nucleotide polymorphism (SNP) in the interleukin-7 (IL7) gene with immune-related adverse events (irAEs) in the CheckMate 025 trial.

Author

Saad, Eddy, primary, Labaki, Chris, additional, Saliby, Renee Maria, additional, Semaan, Karl, additional, Eid, Marc, additional, Sun, Maxine, additional, Sharon, Elad, additional, Vemula, Sai Vikram, additional, Gupta, Saurabh, additional, Van Allen, Eliezer Mendel, additional, Gusev, Alexander, additional, and CHOUEIRI, Toni K., additional

Published
2024
Full Text
View/download PDF

14. Characterizing genomic alterations in patients with metastatic urothelial carcinoma (mUC) treated with enfortumab-vedotin (EV) with a focus on 1q23.3.

Author

Saliby, Renee Maria, primary, Semaan, Karl, additional, Epstein, Ilana B., additional, Liria, Sonsoles, additional, Dall, Christopher, additional, Saad, Eddy, additional, Eid, Marc, additional, Canniff, John, additional, Kwak, Lucia, additional, Berg, Stephanie A., additional, Mantia, Charlene, additional, McGregor, Bradley Alexander, additional, Braun, David A., additional, CHOUEIRI, Toni K., additional, and Bellmunt, Joaquim, additional

Published
2024
Full Text
View/download PDF

17. The role of ablative therapy for primary and oligometastatic renal cell carcinoma

Author

Eid, Marc, Semaan, Karl, Saad, Eddy, Saliby, Renee Maria, Chehade, Razane El Hajj, and McGregor, Bradley A

Abstract

Ablation therapy is emerging as a compelling alternate approach for the management of patients with renal cell carcinoma (RCC), particularly patients who are not surgical candidates. These treatment modalities provide an excellent local control and minimal toxicity, with potential to delay systemic therapy for patients with oligometastatic RCC. This review aims to provide an overview of the role of ablative therapies in the management of patients with localized and oligometastatic RCC.

Published
2024
Full Text
View/download PDF

19. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Takemura, Kosuke, Lemelin, Audreylie, Ernst, Matthew S., Wells, J. Connor, Saliby, Renee Maria, El Zarif, Talal, Labaki, Chris, Basappa, Naveen S., Szabados, Bernadett, Powles, Thomas, Davis, Ian D., Wood, Lori A., Lalani, Aly-Khan A., McKay, Rana R., Lee, Jae-Lyun, Meza, Luis, Pal, Sumanta K., Donskov, Frede, Yuasa, Takeshi, Beuselinck, Benoit, Gebrael, Georges, Agarwal, Neeraj, Choueiri, Toni K., and Heng, Daniel Y.C.

Published
2024
Full Text
View/download PDF

20. Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping

Author

Baca, Sylvan C., primary, Seo, Ji-Heui, additional, Davidsohn, Matthew P., additional, Fortunato, Brad, additional, Semaan, Karl, additional, Sotudian, Shahabbedin, additional, Lakshminarayanan, Gitanjali, additional, Diossy, Miklos, additional, Qiu, Xintao, additional, El Zarif, Talal, additional, Savignano, Hunter, additional, Canniff, John, additional, Madueke, Ikenna, additional, Saliby, Renee Maria, additional, Zhang, Ziwei, additional, Li, Rong, additional, Jiang, Yijia, additional, Taing, Len, additional, Awad, Mark, additional, Chau, Cindy H., additional, DeCaprio, James A., additional, Figg, William D., additional, Greten, Tim F., additional, Hata, Aaron N., additional, Hodi, F. Stephen, additional, Hughes, Melissa E., additional, Ligon, Keith L., additional, Lin, Nancy, additional, Ng, Kimmie, additional, Oser, Matthew G., additional, Meador, Catherine, additional, Parsons, Heather A., additional, Pomerantz, Mark M., additional, Rajan, Arun, additional, Ritz, Jerome, additional, Thakuria, Manisha, additional, Tolaney, Sara M., additional, Wen, Patrick Y., additional, Long, Henry, additional, Berchuck, Jacob E., additional, Szallasi, Zoltan, additional, Choueiri, Toni K., additional, and Freedman, Matthew L., additional

Published
2023
Full Text
View/download PDF

21. Epigenomic signatures as circulating and predictive biomarkers in sarcomatoid renal cell carcinoma

Author

El Zarif, Talal, primary, Semaan, Karl, additional, Eid, Marc, additional, Sep, Ji-Heui, additional, Semaan, Simon Garinet, additional, Davidsohn, Matthew P., additional, Fortunato, Brad, additional, Canniff, John, additional, Nassar, Amin H., additional, Abou Alaiwi, Sarah, additional, Bakouny, Ziad, additional, Lakshmi, Gitanjali, additional, Savigano, Hunter, additional, Lyons, Kevin, additional, Matar, Sayed, additional, Ali, Atef, additional, Saad, Eddy, additional, Saliby, Renee Maria, additional, Cordeiro, Paulo, additional, Zhang, Ziwei, additional, El Ahmar, Nourhan, additional, Nabil Laimon, Yasmine, additional, Labaki, Chris, additional, Shah, Valisha, additional, Freeman, Dory, additional, O'Toole, Jillian, additional, Lee, Gwo-Shu Mary, additional, Hwang, Justin, additional, Pomerantz, Mark, additional, Signoretti, Sabina, additional, Xie, Wanling, additional, Berchuck, Jacob E., additional, Viswanathan, Srinivas R., additional, Van Allen, Eliezer M., additional, Braun, David A., additional, Choueiri, Toni K., additional, Freedman, Matthew L., additional, and Baca, Sylvan C., additional

Published
2023
Full Text
View/download PDF

22. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes

Author

Saliby, Renée Maria, Labaki, Chris, Jammihal, Tejas R., Xie, Wanling, Sun, Maxine, Shah, Valisha, Saad, Eddy, Kane, M. Harry, Kashima, Soki, Sadak, Katherine, El Zarif, Talal, Poduval, Deepak, Motzer, Robert J., Powles, Thomas, Rini, Brian I., Albiges, Laurence, Pal, Sumanta K., McGregor, Bradley A., McKay, Rana R., Signoretti, Sabina, Van Allen, Eliezer M., Shukla, Sachet A., Choueiri, Toni K., and Braun, David A.

Published
2024
Full Text
View/download PDF

23. Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma

Author

Saliby, Renee Maria, primary, El Zarif, Talal, additional, Bakouny, Ziad, additional, Shah, Valisha, additional, Xie, Wanling, additional, Flippot, Ronan, additional, Denize, Thomas, additional, Harry Kane, M, additional, Madsen, Katrine, additional, Ficial, Miriam, additional, Hirsch, Laure, additional, Wei, Xiao, additional, Steinharter, John, additional, Harshman, Lauren, additional, Vaishampayan, Ulka, additional, Severgnini, Mariano, additional, McDermott, David, additional, Mary Lee, Gwo-Shu, additional, Xu, Wenxin, additional, Van Allen, Eliezer, additional, McGregor, Bradley, additional, Signoretti, Sabina, additional, Choueiri, Toni, additional, McKay, Rana, additional, and Braun, David, additional

Published
2023
Full Text
View/download PDF

24. Abstract A029: Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC)

Author

Semaan, Karl, primary, Zarif, Talal El, additional, Eid, Marc, additional, Shah, Valisha, additional, Fortunato, Brad, additional, Saliby, Renee Maria, additional, Nassar, Amin H., additional, Alaiwi, Sarah Abou, additional, Seo, Ji-Heui, additional, Labaki, Chris, additional, Bakouny, Ziad, additional, Matar, Sayed, additional, Ahmar, Nourhan El, additional, Laimon, Yasmin Nabil, additional, Lee, Gwo-Shu Mary, additional, Pomerantz, Mark, additional, Berchuck, Jacob, additional, Signoretti, Sabina, additional, Van Allen, Eliezer, additional, Choueiri, Toni, additional, Braun, David, additional, Freedman, Matthew, additional, and Baca, Sylvan, additional

Published
2023
Full Text
View/download PDF

25. Abstract B019: Clinical and molecular characterization of chromophobe renal cell carcinoma: A focus on immunotherapy based regimens and the tumor immune microenvironment

Author

Alchoueiry, Michel, primary, Labaki, Chris, additional, Zhang, Long, additional, Hou, Yue, additional, Bi, Kevin, additional, Hobeika, Charbel, additional, Wells, J. Connor, additional, Takemura, Kosuke, additional, Bakouny, Ziad, additional, Camp, Sabrina, additional, Priolo, Carmen, additional, Khabibullin, Damir, additional, Schindler, Nicholas, additional, Saliby, Renee Maria, additional, Saad, Eddy, additional, Salem, Samer, additional, Daou, Melissa, additional, McKay, Rana, additional, Pal, Sumanta, additional, Heng, Daniel, additional, Van Allen, Eliezer, additional, Shukla, Sachet, additional, Choueiri, Toni, additional, Braun, David, additional, and Henske, Elizabeth, additional

Published
2023
Full Text
View/download PDF

26. Figure S9 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

Author

Saliby, Renee Maria, primary, El Zarif, Talal, primary, Bakouny, Ziad, primary, Shah, Valisha, primary, Xie, Wanling, primary, Flippot, Ronan, primary, Denize, Thomas, primary, Kane, M. Harry, primary, Madsen, Katrine N., primary, Ficial, Miriam, primary, Hirsch, Laure, primary, Wei, Xiao X., primary, Steinharter, John A., primary, Harshman, Lauren C., primary, Vaishampayan, Ulka N., primary, Severgnini, Mariano, primary, McDermott, David F., primary, Lee, Gwo-Shu Mary, primary, Xu, Wenxin, primary, Van Allen, Eliezer M., primary, McGregor, Bradley A., primary, Signoretti, Sabina, primary, Choueiri, Toni K., primary, McKay, Rana R., primary, and Braun, David A., primary

Published
2023
Full Text
View/download PDF

27. Table S1 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

Author

Saliby, Renee Maria, primary, El Zarif, Talal, primary, Bakouny, Ziad, primary, Shah, Valisha, primary, Xie, Wanling, primary, Flippot, Ronan, primary, Denize, Thomas, primary, Kane, M. Harry, primary, Madsen, Katrine N., primary, Ficial, Miriam, primary, Hirsch, Laure, primary, Wei, Xiao X., primary, Steinharter, John A., primary, Harshman, Lauren C., primary, Vaishampayan, Ulka N., primary, Severgnini, Mariano, primary, McDermott, David F., primary, Lee, Gwo-Shu Mary, primary, Xu, Wenxin, primary, Van Allen, Eliezer M., primary, McGregor, Bradley A., primary, Signoretti, Sabina, primary, Choueiri, Toni K., primary, McKay, Rana R., primary, and Braun, David A., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

Author

Saliby, Renee Maria, primary, El Zarif, Talal, primary, Bakouny, Ziad, primary, Shah, Valisha, primary, Xie, Wanling, primary, Flippot, Ronan, primary, Denize, Thomas, primary, Kane, M. Harry, primary, Madsen, Katrine N., primary, Ficial, Miriam, primary, Hirsch, Laure, primary, Wei, Xiao X., primary, Steinharter, John A., primary, Harshman, Lauren C., primary, Vaishampayan, Ulka N., primary, Severgnini, Mariano, primary, McDermott, David F., primary, Lee, Gwo-Shu Mary, primary, Xu, Wenxin, primary, Van Allen, Eliezer M., primary, McGregor, Bradley A., primary, Signoretti, Sabina, primary, Choueiri, Toni K., primary, McKay, Rana R., primary, and Braun, David A., primary

Published
2023
Full Text
View/download PDF

29. Data from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

Author

Saliby, Renee Maria, primary, El Zarif, Talal, primary, Bakouny, Ziad, primary, Shah, Valisha, primary, Xie, Wanling, primary, Flippot, Ronan, primary, Denize, Thomas, primary, Kane, M. Harry, primary, Madsen, Katrine N., primary, Ficial, Miriam, primary, Hirsch, Laure, primary, Wei, Xiao X., primary, Steinharter, John A., primary, Harshman, Lauren C., primary, Vaishampayan, Ulka N., primary, Severgnini, Mariano, primary, McDermott, David F., primary, Lee, Gwo-Shu Mary, primary, Xu, Wenxin, primary, Van Allen, Eliezer M., primary, McGregor, Bradley A., primary, Signoretti, Sabina, primary, Choueiri, Toni K., primary, McKay, Rana R., primary, and Braun, David A., primary

Published
2023
Full Text
View/download PDF

30. Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC).

Author

Labaki, Chris, Alchoueiry, Michel, Bi, Kevin, Zhang, Long, Hobeika, Charbel, Bakouny, Ziad, El Ahmar, Nourhan, Matar, Sayed, Priolo, Carmen, Khabibullin, Damir, Schindler, Nicholas R., Camp, Sabrina Yvonne, Saliby, Renee Maria, Saad, Eddy, Signoretti, Sabina, Van Allen, Eliezer Mendel, Shukla, Sachet A, Henske, Elizabeth, Choueiri, Toni K., and Braun, David A.

Published
2024
Full Text
View/download PDF

31. Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.

Author

Saad, Eddy, Labaki, Chris, Miron, Benjamin, Park, Jihye, Bakouny, Ziad, Nassar, Amin, Saliby, Renee Maria, Semaan, Karl, Eid, Marc, Meli, Kevin, Nabil Laimon, Yasmin, Geynisman, Daniel M., Kokate, Rutika, Braun, David A., Signoretti, Sabina, McGregor, Bradley Alexander, Plimack, Elizabeth R., Choueiri, Toni K., Van Allen, Eliezer Mendel, and Zibelman, Matthew R.

Published
2024
Full Text
View/download PDF

33. Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.

Author

Saliby, Renee Maria, Xie, Wanling, Wells, J Connor, Saad, Eddy, Eid, Marc, Labaki, Chris, Semaan, Karl, Ferrier, Evan, Lemelin, Audreylie, Suárez, Cristina, Ruiz-Morales, Jose Manuel, Powles, Thomas, Wood, Lori, Ebrahimi, Hedyeh, de Velasco, Guillermo, Takemura, Kosuke null, Agarwal, Neeraj, Braun, David A., Heng, Daniel Yick Chin, and Choueiri, Toni K.

Published
2024
Full Text
View/download PDF

34. Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).

Author

Wells, Connor, Ferrier, Evan, Lemelin, Audreylie, Powles, Thomas, Pal, Sumanta Kumar, Ebrahimi, Hedyeh, Agarwal, Neeraj, Beuselinck, Benoit, Bjarnason, Georg A., Wood, Lori, Canil, Christina M., Saliby, Renee Maria, de Velasco, Guillermo, McKay, Rana R., Tran, Ben, Suárez, Cristina, Templeton, Arnoud J., Choueiri, Toni K., and Heng, Daniel Yick Chin

Published
2024
Full Text
View/download PDF

35. Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.

Author

Gupta, Mehul, Wells, Connor, Regan, Meredith M., Xie, Wanling, Navani, Vishal, Saliby, Renee Maria, Basappa, Naveen S., Donskov, Frede, Yuasa, Takeshi, Takemura, Kosuke null, Kollmannsberger, Christian K., Crumbaker, Megan, Lalani, Aly-Khan A., Powles, Thomas, Pal, Sumanta Kumar, McKay, Rana R., Lee, Jae-Lyun, Kanesvaran, Ravindran, Choueiri, Toni K., and Heng, Daniel Yick Chin

Published
2024
Full Text
View/download PDF

37. Functional assessment using 3D movement analysis can better predict health-related quality of life outcomes in patients with adult spinal deformity: a machine learning approach

Author

Mekhael, Elio, primary, El Rachkidi, Rami, additional, Saliby, Renee Maria, additional, Nassim, Nabil, additional, Semaan, Karl, additional, Massaad, Abir, additional, Karam, Mohamad, additional, Saade, Maria, additional, Ayoub, Elma, additional, Rteil, Ali, additional, Jaber, Elena, additional, Chaaya, Celine, additional, Abi Nahed, Julien, additional, Ghanem, Ismat, additional, and Assi, Ayman, additional

Published
2023
Full Text
View/download PDF

39. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19

Author

Gulati, Shuchi, Hsu, Chih-Yuan, Shah, Surbhi, Shah, Pankil K., Zon, Rebecca, Alsamarai, Susan, Awosika, Joy, El-Bakouny, Ziad, Bashir, Babar, Beeghly, Alicia, Berg, Stephanie, de-la-Rosa-Martinez, Daniel, Doroshow, Deborah B., Egan, Pamela C., Fein, Joshua, Flora, Daniel B., Friese, Christopher R., Fromowitz, Ariel, Griffiths, Elizabeth A., Hwang, Clara, Jani, Chinmay, Joshi, Monika, Khan, Hina, Klein, Elizabeth J., Heater, Natalie Knox, Koshkin, Vadim S., Kwon, Daniel H., Labaki, Chris, Latif, Tahir, McKay, Rana R., Nagaraj, Gayathri, Nakasone, Elizabeth S., Nonato, Taylor, Polimera, Hyma V., Puc, Matthew, Razavi, Pedram, Ruiz-Garcia, Erika, Saliby, Renee Maria, Shastri, Aditi, Singh, Sunny R.K., Tagalakis, Vicky, Vilar-Compte, Diana, Weissmann, Lisa B., Wilkins, Cy R., Wise-Draper, Trisha M., Wotman, Michael T., Yoon, James J., Mishra, Sanjay, Grivas, Petros, Shyr, Yu, Warner, Jeremy L., Connors, Jean M., Shah, Dimpy P., Rosovsky, Rachel P., Gulati, Shuchi, Hsu, Chih-Yuan, Shah, Surbhi, Shah, Pankil K., Zon, Rebecca, Alsamarai, Susan, Awosika, Joy, El-Bakouny, Ziad, Bashir, Babar, Beeghly, Alicia, Berg, Stephanie, de-la-Rosa-Martinez, Daniel, Doroshow, Deborah B., Egan, Pamela C., Fein, Joshua, Flora, Daniel B., Friese, Christopher R., Fromowitz, Ariel, Griffiths, Elizabeth A., Hwang, Clara, Jani, Chinmay, Joshi, Monika, Khan, Hina, Klein, Elizabeth J., Heater, Natalie Knox, Koshkin, Vadim S., Kwon, Daniel H., Labaki, Chris, Latif, Tahir, McKay, Rana R., Nagaraj, Gayathri, Nakasone, Elizabeth S., Nonato, Taylor, Polimera, Hyma V., Puc, Matthew, Razavi, Pedram, Ruiz-Garcia, Erika, Saliby, Renee Maria, Shastri, Aditi, Singh, Sunny R.K., Tagalakis, Vicky, Vilar-Compte, Diana, Weissmann, Lisa B., Wilkins, Cy R., Wise-Draper, Trisha M., Wotman, Michael T., Yoon, James J., Mishra, Sanjay, Grivas, Petros, Shyr, Yu, Warner, Jeremy L., Connors, Jean M., Shah, Dimpy P., and Rosovsky, Rachel P.

Abstract

IMPORTANCE: Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking. OBJECTIVE: To assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: This registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection. Data were accrued from March 2020 to December 2021 and analyzed from December 2021 to October 2022. EXPOSURE: Treatments of interest (TOIs) (endocrine therapy, vascular endothelial growth factor inhibitors/tyrosine kinase inhibitors [VEGFis/TKIs], immunomodulators [IMiDs], immune checkpoint inhibitors [ICIs], chemotherapy) vs reference (no systemic therapy) in 3 months prior to COVID-19. MAIN OUTCOMES AND MEASURES: Main outcomes were (1) venous thromboembolism (VTE) and (2) arterial thromboembolism (ATE). Secondary outcome was severity of COVID-19 (rates of intensive care unit admission, mechanical ventilation, 30-day all-cause mortality following TEEs in TOI vs reference group) at 30-day follow-up. RESULTS: Of 4988 hospitalized patients with cancer (median [IQR] age, 69 [59-78] years; 2608 [52%] male), 1869 had received 1 or more TOIs. Incidence of VTE was higher in all TOI groups: endocrine therapy, 7%; VEGFis/TKIs, 10%; IMiDs, 8%; ICIs, 12%; and chemotherapy, 10%, compared with patients not receiving systemic therapies (6%). In multivariable log-binomial regression analyses, relative risk of VTE (adjusted risk ratio [aRR], 1.33; 95% CI, 1.04-1.69) but not ATE (aRR, 0.81; 95% CI, 0.56-1.16) was significantly higher in those exposed to all TOIs pooled together vs those with no exposure. Among individual drugs, ICIs were significantly associated with VTE (aRR, 1.45; 95% CI, 1.01-2.07). Also noted were significant associations between VTE and active and progressing ca

Published
2023

40. Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens.

Author

Labaki, Chris, primary, Bakouny, Ziad, additional, Wells, J Connor, additional, Takemura, Kosuke, additional, Saliby, Renee Maria, additional, Meza, Luis A, additional, Gebrael, Georges, additional, Porta, Camillo, additional, Lee, Jae-Lyun, additional, Basappa, Naveen S., additional, De Velasco, Guillermo, additional, McKay, Rana R., additional, Pal, Sumanta Monty, additional, Agarwal, Neeraj, additional, Donskov, Frede, additional, Braun, David A., additional, Henske, Elizabeth, additional, Xie, Wanling, additional, Heng, Daniel Yick Chin, additional, and Choueiri, Toni K., additional

Published
2023
Full Text
View/download PDF

41. Additional file 1 of Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Author

Johnson, Douglas B., Atkins, Michael B., Hennessy, Cassandra, Wise-Draper, Trisha, Heilman, Hannah, Awosika, Joy, Bakouny, Ziad, Labaki, Chris, Saliby, Renee Maria, Hwang, Clara, Singh, Sunny R. K., Balanchivadze, Nino, Friese, Christopher R., Fecher, Leslie A., Yoon, James J., Hayes-Lattin, Brandon, Bilen, Mehmet A., Castellano, Cecilia A., Lyman, Gary H., Tachiki, Lisa, Shah, Sumit A., Glover, Michael J., Flora, Daniel B., Wulff-Burchfield, Elizabeth, Kasi, Anup, Abbasi, Saqib H., Farmakiotis, Dimitrios, Viera, Kendra, Klein, Elizabeth J., Weissman, Lisa B., Jani, Chinmay, Puc, Matthew, Fahey, Catherine C., Reuben, Daniel Y., Mishra, Sanjay, Beeghly-Fadiel, Alicia, French, Benjamin, and Warner, Jeremy L.

Abstract

Additional file 1: Supplemental Table 1. Outcomes summarized over full patient cohort. Supplementary Table 2. Organ function in hospitalized patients based on therapy type. Supplemental Table 3. Survival in patients without active cancer or treatment in the previous 3 months.

Published
2023
Full Text
View/download PDF

42. Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center.

Author

Saliby, Renee Maria, primary, Labaki, Chris, additional, Xie, Wanling, additional, Nonato, Taylor, additional, Schmidt, Andrew Lachlan, additional, Bakouny, Ziad, additional, Xu, Wenxin, additional, Ravi, Praful, additional, Braun, David A., additional, Hirsch, Michelle S., additional, McKay, Rana R., additional, Choueiri, Toni K., additional, and McGregor, Bradley Alexander, additional

Published
2022
Full Text
View/download PDF

43. Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.

Author

Labaki, Chris, primary, Zhang, Long, additional, Hou, Yue, additional, Bi, Kevin, additional, Hobeika, Charbel, additional, Bakouny, Ziad, additional, Camp, Sabrina Yvonne, additional, Priolo, Carmen, additional, Khabibullin, Damir, additional, Schindler, Nicholas, additional, Alchoueiry, Michel, additional, Denize, Thomas, additional, Saliby, Renee Maria, additional, Matar, Sayed, additional, Signoretti, Sabina, additional, Van Allen, Eliezer Mendel, additional, Shukla, Sachet A., additional, Braun, David A., additional, Henske, Elizabeth, additional, and Choueiri, Toni K., additional

Published
2022
Full Text
View/download PDF

44. Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.

Author

Saliby, Renee Maria, primary, Jammihal, Tejas, additional, Labaki, Chris, additional, Xie, Wanling, additional, Motzer, Robert J., additional, Powles, Thomas, additional, Rini, Brian I., additional, Albiges, Laurence, additional, Pal, Sumanta K., additional, McKay, Rana R., additional, Signoretti, Sabina, additional, Shukla, Sachet A., additional, Van Allen, Eliezer Mendel, additional, Braun, David A., additional, and Choueiri, Toni K., additional

Published
2022
Full Text
View/download PDF

45. Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.

Author

Xu, Wenxin, primary, Bharadwaj, Maheetha, additional, Birch, Grace, additional, Schindler, Nicholas, additional, Labaki, Chris, additional, Saliby, Renee Maria, additional, Bakouny, Ziad, additional, Freeman, Dory, additional, O'Toole, Jillian, additional, Lee, Gwo-Shu Mary, additional, McGregor, Bradley Alexander, additional, Hirsch, Michelle S., additional, Shukla, Sachet A., additional, McDermott, David F., additional, Signoretti, Sabina, additional, Romee, Rizwan, additional, Choueiri, Toni K., additional, and Braun, David A., additional

Published
2022
Full Text
View/download PDF

49. Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis

Author

Gupta, Mehul, Wells, Connor, Regan, Meredith M., Xie, Wanling, Navani, Vishal, Saliby, Renee Maria, Basappa, Naveen S., Donskov, Frede, Yuasa, Takeshi, Takemura, Kosuke, Kollmannsberger, Christian K., Crumbaker, Megan, Lalani, Aly-Khan A., Powles, Thomas, Ebrahimi, Hedyeh, McKay, Rana R., Lee, Jae-Lyun, Kanesvaran, Ravindran, Choueiri, Toni K., and Heng, Daniel Y.C.

Abstract

In this international, multicenter study of patients with metastatic renal cell carcinoma who received first-line systemic therapy, those with intermediate/poor risk treated with doublet immune checkpoint blockade therapy experienced a longer period alive and free from systemic therapy than those treated with VEGFR inhibitor monotherapy.

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results